New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 21, 2014
10:20 EDTCDNS, PLCE, IRF, KRE, AMPE, TER, CSOD, JRJCHigh option volume stocks
High option volume stocks: TER IRF JRJC AMPE PLCE XEO SYF CSOD KRE CDNS
News For TER;IRF;JRJC;AMPE;PLCE;CSOD;KRE;CDNS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 29, 2015
12:38 EDTPLCEChildren's Place management to meet with Mizuho
Subscribe for More Information
June 24, 2015
10:00 EDTTEROn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Autoliv (ALV) downgraded to Sell from Neutral at Goldman... Catamaran (CTRX) downgraded to Neutral from Buy at UBS... Citi (C) downgraded to Hold from Buy at Deutsche Bank... Esperion (ESPR) downgraded to Neutral from Outperform at Credit Suisse... Fortinet (FTNT) downgraded to Neutral from Buy at Citi... General Motors (GM) downgraded to Neutral from Buy at Goldman... Goldman Sachs (GS) downgraded to Hold from Buy at Deutsche Bank... IBERIABANK (IBKC) downgraded to Neutral from Outperform at Baird... Independent Bank (INDB) downgraded to Underperform from Neutral at Baird... Inphi (IPHI) downgraded to Market Perform from Outperform at Northland... MoneyGram (MGI) downgraded to Neutral from Outperform at Macquarie... Sensata (ST) downgraded to Hold from Buy at Cross Research... Teradyne (TER) downgraded to Buy from Conviction Buy at Goldman... Alcobra (ADHD) downgraded to Hold from Speculative Buy at WBB Securities.
07:12 EDTTERTeradyne downgraded to Buy from Conviction Buy at Goldman
Subscribe for More Information
June 22, 2015
10:47 EDTCDNSCadence Design and Applied Materials collaborate on joint development program
Subscribe for More Information
08:31 EDTAMPEAmpio announces additional study ersults for Optina
Ampio announced that further data analysis from the 12-week multi-center, placebo-controlled, double-masked randomized trial identified a reversal of pathological changes and a synergistic effect with other medication. As previously reported, oral treatment with Optina has been shown to be safe and confer significant improvements in visual acuity (VA) and reductions in central retinal thickness in patients with diabetic macular edema when given the optimal dose. An independent specialized ophthalmology company reviewed a representative set of images of the eye from the trial and identified positive changes in Optina treated patients compared to placebo. These changes included the reversal of complications such as cystic lesions and subretinal fluid. Additionally, analysis revealed that 69% of the patients in the Optina™ Study received a standard of care medication that manages kidney-induced high blood pressure. The drugs referred to as ACE Inhibitors or ARBs are commonly prescribed to diabetic patients. When this group received the optimal Optina™ dose, they showed a six-letter improvement compared to placebo, regardless of whether or not they previously had anti-VEGF eye injections. There was a significant 34 micron reduction in central retinal thickness over placebo. 60% of these eyes showed a restoration of at least one line of vision compared to only 27% of placebo.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use